logo
  

Hain Celestial Maintains FY22 Outlook; Q1 Results Top Estimates - Quick Facts

While reporting financial results for the first quarter on Tuesday, organic and natural products company Hain Celestial Group, Inc. (HAIN) maintained its adjusted net sales growth and adjusted EBITDA growth guidance for the full year 2022.

For fiscal 2022, the company continues to project adjusted net sales growth in the low single digit percentage and adjusted EBITDA growth in the mid-to-high single digit percentage.

On average, 11 analysts polled by Thomson Reuters expect the company to report a sales decline of 2.6 percent to $1.92 billion for the year.

For the first quarter, net income soared to $19.41 million or $0.20 per share from $0.49 million $0.00 per share in the prior-year quarter. Excluding items, adjusted earnings for the quarter was $0.25 per share, compared to $0.27 per share in the year-ago quarter.

Net sales for the quarter decreased 8.8 percent to $454.90 million from $498.63 million in the same quarter last year. Net sales also declined 11 percent on a constant currency basis and were flat on an organic basis.

The Street was looking for earnings of $0.24 per share on revenues of $442.48 million for the quarter.

The company also said it expects net sales to be down low single digit on an adjusted basis in the first half of fiscal year 2022 and up by mid to high single digit in the second half.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Cargill, Inc., a privately held food company, is recalling certain chocolate products containing recalled Jif peanut butter due to the potential for salmonella contamination, the U.S. Food and Drug Administration said. The recall involves 795, 8-ounce boxes of Wilbur brand products, such as Milk and Dark Chocolate Covered Peanut Butter Ritz Crackers, Peanut Butter Meltaways... The U.S. Food and Drug Administration approved Regeneron Pharmaceuticals, Inc.'s Dupixent (dupilumab) to treat eosinophilic esophagitis or EoE, a chronic immune disorder. It is the first FDA approval to treat EoE in adults and pediatric patients 12 years and older weighing at least 40 kilograms. Food products maker J. M. Smucker Co. has recalled select Jif peanut butter products sold in the United States due to potential Salmonella contamination, the U.S. Food and Drug Administration said. The recall involves various creamy, crunchy, natural, no added sugar, and reduced fat peanut butter, among others with lot codes 1274425 - 2140425.
RELATED NEWS
Follow RTT